ASAQ

DRUG4 trials

Sponsors

Centre Muraz, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Malaria

Phase 1

Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali

CompletedNCT02627456

National Institute of Allergy and Infectious Diseases (NIAID)Malaria

Start: 2015-12-09End: 2018-07-03Updated: 2021-04-21

Phase 3

Efficacy study of antimalarial drugs in Senegal

Active, not recruitingPACTR202003802011316

Start: 2018-09-01Target: 500Updated: 2026-01-27

Phase 4

ANC & Malaria Diagnostic in Pregnancy

CompletedNCT01703884

Centre MurazMalaria

Start: 2012-08-31End: 2014-12-31Updated: 2015-07-31

RecruitingPACTR202301796134887

Start: 2022-11-01Target: 1350Updated: 2026-01-27

Related Papers

Efficacies of artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial.

2025-08-193 citations

Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.

2021-11-1868 citations

Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate <i>in vivo Plasmodium falciparum</i> malaria parasite growth in the context of pre-existing immunity.

2018-01-0134 citations